Yan Liu1, Xiao-Yan Ke2, Lei Tian1, Wei Wan1, Fei Dong1, Jing Wang1. 1. Department of Hematology, The Third Hosital of Peking University, Beijing 100191, China. 2. Department of Hematology, The Third Hosital of Peking University, Beijing 100191, China. E-mail: xykbysy@163.com.
Abstract
OBJECTIVE: To study the relationship between bone markers and the progression of multiple myeloma (MM). METHODS: Retrospective analysis of 100 MM patients hospitalized in the Department of Hematology of Peking University Third Hospital between March 2012 and March 2016 was performed. The patients were divided into Group A (n=33), which consisted of patients with complete remission (CR), very good partial remission (VGPR), partial remission (PR) and stable disease (SD) and group B (n=67), which consisted of newly diagnosed patients and patients with progression of disease (PD). Serum N-MID osteocalcin (N-MID osteocalcin), procollagen I amino-terminal propeptide (PINP) and β-C-terminal telopeptide of type I collagen (β-CTx) were measured by electrochemiluminescence immunoassay (ECLIA). Multiple logistic regression was used to analyzed the correlation between bone markers and PD of MM. RESULTS: PINP and β-CTx were significantly higher in group B than that in group A, mean 51.41 ng/ml vs 77.48 ng/ml (P=0.026); 0.52 ng/ml vs 1.03 ng/ml(P=0.01) respectively. There was no significant difference in N-MID level between the 2 groups (P=0.27). Multivariate analysis showed β-CTx was an independent risk factor for PD of MM. CONCLUSION: Serum PINP and β-CTx levels are different in PD and stable stages of MM, and β-CTx can be used as an index for monitoring of PD of MM.
OBJECTIVE: To study the relationship between bone markers and the progression of multiple myeloma (MM). METHODS: Retrospective analysis of 100 MM patients hospitalized in the Department of Hematology of Peking University Third Hospital between March 2012 and March 2016 was performed. The patients were divided into Group A (n=33), which consisted of patients with complete remission (CR), very good partial remission (VGPR), partial remission (PR) and stable disease (SD) and group B (n=67), which consisted of newly diagnosed patients and patients with progression of disease (PD). Serum N-MID osteocalcin (N-MID osteocalcin), procollagen I amino-terminal propeptide (PINP) and β-C-terminal telopeptide of type I collagen (β-CTx) were measured by electrochemiluminescence immunoassay (ECLIA). Multiple logistic regression was used to analyzed the correlation between bone markers and PD of MM. RESULTS:PINP and β-CTx were significantly higher in group B than that in group A, mean 51.41 ng/ml vs 77.48 ng/ml (P=0.026); 0.52 ng/ml vs 1.03 ng/ml(P=0.01) respectively. There was no significant difference in N-MID level between the 2 groups (P=0.27). Multivariate analysis showed β-CTx was an independent risk factor for PD of MM. CONCLUSION: Serum PINP and β-CTx levels are different in PD and stable stages of MM, and β-CTx can be used as an index for monitoring of PD of MM.